查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1657638

比較藥物採購市場 - 全球產業規模、佔有率、趨勢、機會和預測，按服務類型、治療領域、最終用戶、地區和競爭細分，2020-2030 年預測

Comparator Drug Sourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service Type, By Therapeutic Area, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球比較藥物採購市場價值為 13.4 億美元，預計到 2030 年將達到 18.8 億美元，複合年成長率為 5.74%。製藥和生物技術公司需要比較藥物來確定新療法的有效性和安全性。對更高效、更具成本效益的臨床試驗的持續追求進一步推動了市場的發展，並且越來越注重縮短開發時間。由於監管機構越來越要求對新療法和現有療法進行清晰、標準化的比較，因此對強大且符合監管要求的採購模式的需求也起著至關重要的作用。因此，公司正在採用分散和虛擬臨床試驗，這有望增加從可靠供應商採購比較藥物的需求。

市場概況
預測期 2026-2030
2024 年市場規模 13.4 億美元
2030 年市場規模 18.8 億美元
2025-2030 年複合年成長率 5.74％
成長最快的領域 腫瘤學
最大的市場 北美洲

影響市場成長的主要趨勢包括監管框架的擴大和臨床試驗的日益複雜性。隨著越來越多的生物製劑和生物相似藥進入市場，對專門的比較藥物採購的需求也日益成長，以確保符合國際標準。科技的進步使得臨床試驗的管理和追蹤變得更容易，包括使用數位工具和人工智慧進行患者招募和資料監測。此外，使用進階分析技術簡化採購流程的情況正在激增，從而提高了採購比較藥物的速度和準確性。物流和冷鏈管理的創新進一步支持了這些趨勢，確保對照藥物及時安全地運送到全球臨床試驗地點。

市場機會無限，尤其是隨著外包臨床試驗管理的採用日益增加。製藥公司認知到利用外部供應商進行比較藥物採購而不是內部管理流程可以節省成本和時間。合約研究組織（CRO）的成長進一步放大了這一趨勢，CRO在處理對照藥物的採購和物流方面發揮著至關重要的作用。然而，挑戰依然存在，例如在全球供應鏈中斷的情況下確保藥品品質和供應的一致性。此外，跨多個地區的監管合規複雜性仍然是許多尋求在新市場擴展業務的公司面臨的障礙。確保採購過程的透明度和維持藥品完整性的高標準是競爭環境中持續關注的問題。隨著市場的不斷發展，這些挑戰需要被解決。

主要市場促進因素

臨床試驗數量不斷增加

法規遵從性和標準化

臨床試驗外包的興起

主要市場挑戰

採購成本高

複雜的監理合規性

主要市場趨勢

注重永續性和道德採購

採購流程中採用數位技術

分段洞察

服務類型洞察

最終用戶洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球比較藥物採購市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按服務類型（採購、供應鏈管理、監管和品質合規、包裝和標籤、諮詢服務）
    • 依治療領域（腫瘤科、心血管疾病科、神經科、傳染病科、免疫科、代謝障礙科、罕見疾病科、其他科）
    • 按最終用戶（製藥和生物技術公司、合約研究組織 (CRO)、學術和研究機構、其他）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第 6 章：北美比較藥物採購市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 7 章：歐洲比較藥物採購市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區比較藥物採購市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲比較藥物採購市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲比較藥物採購市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如果有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Clinigen Limited
  • BAP Pharma Group Limited
  • Thermo Fisher Scientific Inc.
  • Laboratory Corporation of America Holdings
  • Catalent, Inc.
  • Almac Group Limited
  • McKesson Corporation
  • Euromed Pharma Srl
  • Sharp Services, LLC
  • PCI Pharma Services

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 27542

Global Comparator Drug Sourcing Market was valued at USD 1.34 Billion in 2024 and is expected to reach USD 1.88 Billion in the forecast period with a CAGR of 5.74% through 2030. The Global Comparator Drug Sourcing Market is poised for significant growth due to the increasing demand for clinical trials, especially with the rise of personalized medicine and biologics. Pharmaceutical and biotechnology companies require comparator drugs to establish the efficacy and safety of novel treatments. The ongoing push for more efficient and cost-effective clinical trials further drives the market, with a growing focus on minimizing development timelines. The need for robust and regulatory-compliant sourcing models also plays a critical role, as regulatory bodies increasingly require clear and standardized comparisons between new and existing therapies. As a result, companies are adopting decentralized and virtual clinical trials, which are expected to amplify the demand for sourcing comparator drugs from reliable suppliers.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.34 Billion
Market Size 2030USD 1.88 Billion
CAGR 2025-20305.74%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key trends shaping the growth of the market include the expansion of regulatory frameworks and the rising complexity of clinical trials. The increasing number of biologics and biosimilars entering the market has created a growing need for specialized comparator drug sourcing to ensure compliance with international standards. Advancements in technology have enabled better management and tracking of clinical trials, including the use of digital tools and AI for patient recruitment and data monitoring. Moreover, there is a surge in the use of advanced analytics to streamline sourcing processes, improving both the speed and accuracy of sourcing comparator drugs. Innovations in logistics and cold chain management further support these trends, ensuring the timely and secure delivery of comparator drugs to clinical trial sites globally.

Opportunities in the market are abundant, especially with the increasing adoption of outsourced clinical trial management. Pharmaceutical companies are recognizing the cost and time-saving benefits of leveraging external suppliers for comparator drug sourcing rather than managing the process in-house. This trend is amplified by the growth of contract research organizations (CROs), which play a crucial role in handling the sourcing and logistics of comparator drugs. However, challenges persist, such as ensuring consistent drug quality and availability amidst global supply chain disruptions. Additionally, the complexity of regulatory compliance across multiple regions remains a barrier for many companies looking to expand their operations in new markets. Ensuring the transparency of the sourcing process and maintaining high standards in drug integrity are ongoing concerns in the competitive landscape. These challenges will need to be addressed as the market continues to evolve.

Key Market Drivers

Growing Number of Clinical Trials

The escalating number of clinical trials worldwide significantly influences the Global Comparator Drug Sourcing Market. As pharmaceutical and biotechnology companies intensify their research and development efforts to introduce innovative therapies, the necessity for reliable comparator drugs becomes paramount. These drugs serve as benchmarks in clinical trials, enabling researchers to assess the efficacy and safety of new investigational drugs. The surge in clinical trials, driven by the increasing prevalence of chronic diseases and the development of new therapies, directly boosts the demand for comparator drugs. According to the Tufts Center for the Study of Drug Development, the top 10 pharmaceutical companies collectively spend over USD 20 million annually on comparator sourcing.

Clinical trials encompass a wide array of therapeutic areas, including oncology, cardiology, neurology, and infectious diseases, among others. Each of these areas requires specific comparator drugs to ensure accurate assessments. The World Health Organization reports that as of January 2024, nearly 479,000 clinical studies were registered globally, a significant increase from 35,742 studies in 2008. This substantial rise in clinical studies underscores the escalating demand for comparator drugs, highlighting their critical role in the drug development process.

The growing number of clinical trials not only increases the demand for comparator drugs but also drives innovation in sourcing strategies. To meet the diverse needs of these trials, pharmaceutical companies and research institutions are exploring various sourcing options, including local and centralized approaches. A recent whitepaper by Patheon discusses the balance between opportunities and challenges in local sourcing for clinical trials, emphasizing the importance of strategic decision-making in comparator drug procurement. This trend towards diversified sourcing strategies reflects the industry's commitment to ensuring the availability and quality of comparator drugs, thereby facilitating the successful execution of clinical trials.

Regulatory Compliance and Standardization

Regulatory compliance and standardization are pivotal drivers in the Global Comparator Drug Sourcing Market, ensuring that clinical trials adhere to stringent quality and safety standards. Regulatory bodies such as the FDA, EMA, and other global agencies have established comprehensive guidelines for clinical trials, emphasizing the necessity of using approved comparator drugs to validate the efficacy and safety of new investigational drugs. These regulations mandate that comparator drugs meet specific quality standards, are sourced from reputable suppliers, and are handled according to Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP). Non-compliance can lead to significant delays, increased costs, and potential invalidation of clinical trial results.

Conducting trials across multiple countries introduces complexities due to varying regional regulations and standards. To navigate these challenges, pharmaceutical companies and Contract Research Organizations (CROs) are adopting standardized procedures for comparator drug sourcing. This approach ensures consistency in drug quality, labeling, and documentation, facilitating smoother regulatory approvals and enhancing the reliability of clinical trial outcomes. In summary, adherence to regulatory compliance and standardization is essential for the integrity of clinical trials. By ensuring that comparator drugs meet established quality standards and are sourced through standardized processes, stakeholders can mitigate risks, reduce delays, and contribute to the successful development of new therapies.

Rise in Outsourcing of Clinical Trials

The increasing trend of outsourcing clinical trials has significantly influenced the Global Comparator Drug Sourcing Market. Pharmaceutical companies and research institutions are increasingly relying on contract research organizations (CROs) to conduct clinical trials. This shift allows sponsors to focus on their core competencies while leveraging the specialized expertise and resources of CROs. As a result, the demand for comparator drugs has surged, as these organizations require high-quality, reliable comparator drugs to validate the efficacy and safety of new treatments. The outsourcing model has proven to be cost-effective, enabling sponsors to reduce operational expenses and accelerate the drug development process. Studies have shown that outsourcing can lead to significant cost savings, with some reports indicating reductions of over 20% in clinical trial costs.

The rise of specialized CROs catering to niche areas of clinical research has further propelled the demand for comparator drugs. These organizations offer tailored services, focusing on specific therapeutic areas or patient populations, thereby enhancing the precision and efficiency of clinical trials. Their expertise in managing complex trials has made them invaluable partners for pharmaceutical companies, leading to an increased need for specialized comparator drugs. The growth of specialized CROs reflects a broader trend towards more personalized and targeted approaches in clinical research, aligning with the industry's shift towards precision medicine.

The adoption of the Functional Service Provider (FSP) model has also contributed to the growth of the comparator drug sourcing market. This model offers flexibility and control over outsourced clinical trials, allowing sponsors to tailor services to their specific needs. The FSP approach is more affordable compared to the full-service model, making it an attractive option for many companies. Its cost-effectiveness and adaptability have led to its widespread adoption, further driving the demand for comparator drugs. The FSP model's emphasis on efficiency and customization aligns with the industry's broader goals of reducing development timelines and costs, thereby accelerating the availability of new therapies to patients. In summary, the outsourcing of clinical trials has been a significant driver of growth in the comparator drug sourcing market. The trend towards outsourcing, the rise of specialized CROs, and the adoption of the FSP model have collectively increased the demand for high-quality comparator drugs, underscoring their essential role in the clinical trial process.

Key Market Challenges

High Sourcing Costs

The Global Comparator Drug Sourcing Market faces significant challenges due to high sourcing costs, which can impede the progress of clinical trials and the development of new therapies. Acquiring comparator drugs often involves substantial financial outlay, driven by high baseline prices of the medications and additional costs of securing them within the supply chain. These expenses include procurement fees, negotiation costs with multiple vendors, and heightened expenses for specialized storage and transportation to maintain drug integrity. Moreover, there's often a need for rigorous quality assurance measures, which add to the overall expenditure. For smaller organizations or those operating within tight budget constraints, these high costs can act as a substantial barrier to entry, limiting their capacity to conduct comprehensive clinical trials.

The financial burden associated with acquiring specific comparator drugs, especially for rare diseases, can deter smaller firms from engaging in critical research, thereby stifling innovation. This situation is exacerbated by the complexities of global supply chains, where fluctuations in currency exchange rates, tariffs, and geopolitical tensions can further increase costs. For instance, recent geopolitical tensions have led U.S. drugmakers to seek alternatives to Chinese partners for manufacturing and raw materials, potentially increasing costs and slowing drug rollouts.

To mitigate these challenges, pharmaceutical companies are exploring alternative sourcing strategies, such as partnering with specialized comparator sourcing vendors or utilizing local sourcing methods to reduce transportation and storage expenses. However, these approaches may not always be feasible, especially when specific comparator drugs are required for clinical trials. The high costs associated with comparator drug sourcing underscore the need for innovative solutions and strategic partnerships to ensure the timely and cost-effective availability of these essential medications for clinical research.

Complex Regulatory Compliance

Navigating the complex regulatory landscape is a significant challenge in the Global Comparator Drug Sourcing Market. Each country or region enforces its own set of regulations governing the approval, importation, and distribution of pharmaceutical products. These regulations often differ in terms of documentation requirements, quality standards, and approval processes, making it difficult for companies to ensure compliance across multiple jurisdictions. For instance, a comparator drug approved in one country may not meet the regulatory standards of another, necessitating additional testing, re-labeling, or even reformulation to satisfy local requirements. This complexity can lead to delays in clinical trials, increased operational costs, and potential legal repercussions if compliance is not meticulously maintained.

Moreover, the evolving nature of regulatory frameworks means that companies must continuously monitor and adapt to changes, further complicating the sourcing process. Inadequate understanding or oversight of these regulations can result in the use of non-compliant comparator drugs, compromising the integrity of clinical trials and potentially endangering patient safety. Therefore, a comprehensive and up-to-date knowledge of global regulatory requirements is essential for companies engaged in comparator drug sourcing to navigate these challenges effectively.

Key Market Trends

Focus on Sustainability and Ethical Sourcing

The Global Comparator Drug Sourcing Market is increasingly emphasizing sustainability and ethical sourcing practices. Pharmaceutical companies are integrating environmentally and socially responsible methods into their supply chains, aiming to reduce ecological footprints and enhance social responsibility. This shift not only aligns with global sustainability goals but also offers economic advantages, such as cost savings, improved efficiency, and enhanced supply chain resilience. For instance, the Indian government has mandated that pharmaceutical companies audit their raw material suppliers at least once a year to ensure quality and safety, thereby promoting ethical sourcing practices.

Implementing sustainable sourcing practices enables pharmaceutical companies to optimize resource use, minimize waste, and reduce energy consumption. These efficiencies lead to lower production costs and improve operational performance. For example, adopting energy-efficient technologies and practices can significantly decrease energy bills and contribute to environmental sustainability. The Indian government's initiative to mandate annual audits of pharmaceutical suppliers underscores the importance of maintaining high-quality standards and ethical sourcing in the industry.

Ethical sourcing ensures that raw materials are obtained responsibly, promoting fair labor practices and supporting community development in supplier regions. This approach not only enhances the company's reputation but also fosters stronger relationships with suppliers and consumers. By prioritizing ethical considerations, companies can attract ethically conscious consumers and investors, leading to increased market share and financial performance. The Indian government's implementation of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) in 2024 aims to curb unethical marketing practices in the pharmaceutical industry, further promoting ethical standards. In summary, the focus on sustainability and ethical sourcing in the comparator drug sourcing market is reshaping the pharmaceutical industry. By adopting these practices, companies can achieve economic benefits, enhance their brand image, and contribute to global sustainability efforts. This trend is expected to continue as stakeholders increasingly value environmental and social responsibility in the pharmaceutical supply chain.

Adoption of Digital Technologies in Sourcing Processes

The Global Comparator Drug Sourcing Market is undergoing a significant transformation with the integration of digital technologies into sourcing processes. The adoption of digital platforms and advanced technologies is streamlining the procurement and management of comparator drugs, enhancing efficiency, transparency, and cost-effectiveness.

One notable development is the establishment of digital platforms that facilitate the direct exchange of comparator drugs among pharmaceutical companies. TransCelerate BioPharma's Comparator Network exemplifies this approach, providing a secure and rapid channel for member companies to source quality comparator products for clinical trials. This initiative reduces reliance on intermediaries, mitigates the risk of counterfeit drugs entering the supply chain, and accelerates trial timelines.

Artificial Intelligence (AI) and Machine Learning (ML) are also playing pivotal roles in optimizing comparator drug sourcing. These technologies enable predictive analytics for demand forecasting, inventory management, and supply chain optimization. AI-driven tools can analyze historical data to predict future needs, ensuring timely availability of comparator drugs and minimizing waste. Additionally, AI enhances the monitoring of drug quality and compliance throughout the supply chain, ensuring that comparator drugs meet the necessary standards for clinical trials.

The implementation of digital technologies in comparator drug sourcing is not only improving operational efficiencies but also fostering greater collaboration among stakeholders. By leveraging digital platforms, pharmaceutical companies, contract research organizations (CROs), and suppliers can share real-time data, coordinate activities more effectively, and respond swiftly to changes in clinical trial requirements. This collaborative approach enhances the overall quality and reliability of comparator drug sourcing, contributing to the success of clinical trials and the advancement of medical research. In summary, the integration of digital technologies into comparator drug sourcing is revolutionizing the market by enhancing efficiency, transparency, and collaboration. As these technologies continue to evolve, they are expected to further streamline sourcing processes, reduce costs, and improve the quality of comparator drugs used in clinical trials.

Segmental Insights

Service Type Insights

Based on the Service Type, Sourcing & Procurement emerged as the dominant segment in the Global Comparator Drug Sourcing Market in 2024. This is due to the escalating number of clinical trials and the increasing complexity of drug development processes. Pharmaceutical companies and contract research organizations (CROs) are increasingly outsourcing drug development activities to specialized service providers. This trend has led to a growing demand for comparator drug sourcing services, as these providers often lack the in-house capabilities to procure comparator drugs. Outsourcing allows companies to focus on their core competencies and reduce costs associated with drug development. The surge in clinical trials, driven by the rising prevalence of chronic diseases and the development of new therapies, has significantly contributed to the demand for efficient sourcing and procurement services. Comparator drugs are essential in establishing the efficacy and safety of new investigational drugs, making their reliable sourcing crucial for the success of clinical trials.

End User Insights

Based on the End User, Pharmaceutical & Biotechnology Companies emerged as the dominant segment in the Global Comparator Drug Sourcing Market in 2024. This dominance is primarily due to their central role in conducting clinical trials, which are essential for the development and approval of new drugs. Comparator drugs are critical in these trials, serving as benchmarks to assess the efficacy and safety of investigational treatments. The increasing complexity and number of clinical trials, driven by the rising prevalence of chronic diseases and the need for innovative therapies, have heightened the demand for reliable comparator drug sourcing. Pharmaceutical and biotechnology companies are at the forefront of this expansion, necessitating efficient and compliant sourcing solutions to meet regulatory standards and ensure the integrity of clinical studies. Furthermore, the growing focus on personalized medicine and the development of biologics and biosimilars have intensified the need for precise and high-quality comparator drugs. Pharmaceutical and biotechnology companies are investing heavily in research and development to cater to these trends, further solidifying their position as the leading end-users in the comparator drug sourcing market.

Regional Insights

North America emerged as the dominant region in the Global Comparator Drug Sourcing Market in 2024. This is primarily driven by several key factors. The United States plays a pivotal role in global clinical trials, accounting for a significant portion of the world's clinical research activities. This concentration of clinical trials in North America necessitates a robust and efficient supply of comparator drugs to meet the demands of diverse and complex study designs. The region's advanced healthcare infrastructure and substantial investments in pharmaceutical research and development further bolster its position in the comparator drug sourcing market. Additionally, North America's stringent regulatory environment ensures high standards for clinical trials, driving the need for precise and reliable comparator drugs. The region's commitment to maintaining rigorous quality and compliance standards in clinical research contributes to its dominance in the global comparator drug sourcing market.

Key Market Players

  • Clinigen Limited
  • BAP Pharma Group Limited
  • Thermo Fisher Scientific Inc.
  • Laboratory Corporation of America Holdings
  • Catalent, Inc.
  • Almac Group Limited
  • McKesson Corporation
  • Euromed Pharma S.r.l.
  • Sharp Services, LLC
  • PCI Pharma Services

Report Scope:

In this report, the Global Comparator Drug Sourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Comparator Drug Sourcing Market, By Service Type:

  • Sourcing & Procurement
  • Supply Chain Management
  • Regulatory & Quality Compliance
  • Packaging & Labelling
  • Consulting Services

Comparator Drug Sourcing Market, By Therapeutic Area:

  • Oncology
  • Cardiovascular Diseases
  • Neurology
  • Infectious Diseases
  • Immunology
  • Metabolic Disorders
  • Rare Diseases
  • Others

Comparator Drug Sourcing Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutions
  • Others

Comparator Drug Sourcing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Comparator Drug Sourcing Market.

Available Customizations:

Global Comparator Drug Sourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Comparator Drug Sourcing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Service Type (Sourcing & Procurement, Supply Chain Management, Regulatory & Quality Compliance, Packaging & Labelling, Consulting Services)
    • 5.2.2. By Therapeutic Area (Oncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Immunology, Metabolic Disorders, Rare Diseases, Others)
    • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutions, Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Comparator Drug Sourcing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Service Type
    • 6.2.2. By Therapeutic Area
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Comparator Drug Sourcing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Service Type
        • 6.3.1.2.2. By Therapeutic Area
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Comparator Drug Sourcing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Service Type
        • 6.3.2.2.2. By Therapeutic Area
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Comparator Drug Sourcing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Service Type
        • 6.3.3.2.2. By Therapeutic Area
        • 6.3.3.2.3. By End User

7. Europe Comparator Drug Sourcing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Service Type
    • 7.2.2. By Therapeutic Area
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Comparator Drug Sourcing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Service Type
        • 7.3.1.2.2. By Therapeutic Area
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Comparator Drug Sourcing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Service Type
        • 7.3.2.2.2. By Therapeutic Area
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Comparator Drug Sourcing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Service Type
        • 7.3.3.2.2. By Therapeutic Area
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Comparator Drug Sourcing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Service Type
        • 7.3.4.2.2. By Therapeutic Area
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Comparator Drug Sourcing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Service Type
        • 7.3.5.2.2. By Therapeutic Area
        • 7.3.5.2.3. By End User

8. Asia-Pacific Comparator Drug Sourcing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Service Type
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Comparator Drug Sourcing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Service Type
        • 8.3.1.2.2. By Therapeutic Area
        • 8.3.1.2.3. By End User
    • 8.3.2. India Comparator Drug Sourcing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Service Type
        • 8.3.2.2.2. By Therapeutic Area
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Comparator Drug Sourcing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Service Type
        • 8.3.3.2.2. By Therapeutic Area
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Comparator Drug Sourcing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Service Type
        • 8.3.4.2.2. By Therapeutic Area
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Comparator Drug Sourcing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Service Type
        • 8.3.5.2.2. By Therapeutic Area
        • 8.3.5.2.3. By End User

9. South America Comparator Drug Sourcing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Service Type
    • 9.2.2. By Therapeutic Area
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Comparator Drug Sourcing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Service Type
        • 9.3.1.2.2. By Therapeutic Area
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Comparator Drug Sourcing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Service Type
        • 9.3.2.2.2. By Therapeutic Area
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Comparator Drug Sourcing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Service Type
        • 9.3.3.2.2. By Therapeutic Area
        • 9.3.3.2.3. By End User

10. Middle East and Africa Comparator Drug Sourcing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Service Type
    • 10.2.2. By Therapeutic Area
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Comparator Drug Sourcing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Service Type
        • 10.3.1.2.2. By Therapeutic Area
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Comparator Drug Sourcing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Service Type
        • 10.3.2.2.2. By Therapeutic Area
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Comparator Drug Sourcing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Service Type
        • 10.3.3.2.2. By Therapeutic Area
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Clinigen Limited
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. BAP Pharma Group Limited
  • 14.3. Thermo Fisher Scientific Inc.
  • 14.4. Laboratory Corporation of America Holdings
  • 14.5. Catalent, Inc.
  • 14.6. Almac Group Limited
  • 14.7. McKesson Corporation
  • 14.8. Euromed Pharma S.r.l.
  • 14.9. Sharp Services, LLC
  • 14.10. PCI Pharma Services

15. Strategic Recommendations

16. About Us & Disclaimer